13 Best Growth Stocks Under $25 to Buy Right Now
Recently, there have been concerns around the surge of fraudulent loans and private credit quality issues in the US.
Takeda Pharmaceutical Co Ltd (TAK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 3,864,600 | $56,577,744 | +18% | 0.07% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,828,778 | $41,413,310 | +133% | 0.03% |
| 3. | Millennium Management Israel Englander | 2,556,206 | $37,422,856 | -18% | 0.02% |
| 4. | 1,608,700 | $23,551,368 | +90% | 0% | |
| 5. | Quantinno Capital Hoon Kim | 973,855 | $14,257,249 | +23% | 0.04% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,404,129 | $196,236,449 | 0.04% | |
| 2. | 7,690,415 | $112,587,715 | 0.01% | |
| 3. | 5,893,969 | $86,287,707 | 0.01% | |
| 4. | 4,953,331 | $72,516,766 | 0.01% | |
| 5. | 4,186,946 | $61,296,893 | 0% |
News See All
Takeda Pharmaceutical Company Limited (TAK) Advances γδ T Cell Cancer Treatments
Takeda Pharmaceutical Company Limited (NYSE:TAK), a global biopharmaceutical leader, is advancing cancer treatment through novel immuno-oncology strategies focused on the innate immune system.
11 Best Cancer Stocks to Buy Right Now
Cancer remains the second leading cause of death globally, after heart disease.
13 Best Japanese Stocks to Buy According to Hedge Funds
Additionally, Japanese government bond yields also moved higher. On Monday, the yield on the 10-year government bond increased by 5.5 basis points to reach 1.554% at 11.20 a.m. local time.
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now.
Takeda Reports Adcetris Combo Approved by EC for Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (NYSE:TAK)'s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized by the European Commission on June 3, 2025, for newly diagnosed adult patients...
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q4 2024 Earnings Call Transcript
Christopher O’Reilly: Thank you very much for taking time out of their busy schedule to join our earnings announcement for FY '24 for Takeda. I'm the master of ceremony, Head of IR.
12 Best Low Price Pharma Stocks To Invest In Right Now
Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the ...
12 Best Japanese Stocks To Buy in 2025
As the dangers of natural disasters increase and the expenses of social security continue to rise, the International Monetary Fund says Japan has to take quick action to strengthen its fiscal situation...
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Earnings Call Transcript
Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind everyone that we’ll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform...
Hedge Fund Resource Center Billionaire Hedge Funds
